Affiliation:
1. Billström Veterinary Services, VCA Parkdale Animal Hospital, Newburgh, IN
2. Vetsuisse Faculty, University of Zürich, Zürich, Switzerland
Abstract
Abstract
OBJECTIVE
This case report describes a cat with severe erythrocytosis (Hct, 80%), which after initial treatment with hydroxyurea has gone into remission for over 3 years.
ANIMAL
A 1-year-old neutered male American Maine Coon crossbred cat.
CLINICAL PRESENTATION, PROGRESSION, AND PROCEDURES
A 1-year-old neutered male American Maine Coon crossbred domestic cat was presented with acute neurologic signs, systolic heart murmur, and extreme erythrocytosis (Hct, 80%; normal interval, 30% to 48%). There were no clinical signs of dehydration, and several diagnostic tests for absolute erythrocytosis did not identify an underlying cause. A presumptive diagnosis of primary erythrocytosis (polycythemia vera [P vera], a myeloproliferative disease) was made.
TREATMENT AND OUTCOME
Repeated phlebotomies were declined by the owner, and thus the cat was treated with oral hydroxyurea. The neurologic signs, heart murmur, and erythrocytosis resolved within 2 months (Hct, 41%). Treatment with hydroxyurea was continued for 2 years and then discontinued. The Hct remained in the normal range (between 37% and 44%) during a 3-year observation period.
CLINICAL RELEVANCE
This case illustrates the challenges of determining a precise cause of erythrocytosis. The extreme erythrocytosis reverted after treatment with hydroxyurea and did not recur even after drug withdrawal, suggesting an undefined singular or multifactorial cause of the erythrocytosis rather than a primary absolute erythrocytosis, such as P vera. The reversibility of this cat’s erythrocytosis suggested that in select cases the discontinuation of treatment is warranted.
Publisher
American Veterinary Medical Association (AVMA)
Reference5 articles.
1. Polycythemia;Hasler AH,2000
2. Primary erythrocytosis in the cat: treatment with hydroxyurea;Watson DJ,1994
3. Kelly. Erythrocytosis in dogs and cats: diagnosis and management;Nitsche E,2004
4. Polycythemia vera (PV): update on emerging treatment options;Benevolo G,2021
5. Hydroxyurea;Plumb DC,2018